Overview

A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the tolerability and efficacy of different doses of duloxetine in patients with major depressive disorder.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride
Criteria
Inclusion Criteria:

- Outpatients at least 18 years of age (male and/or female) who meet criteria for major
depressive disorder (MDD) as defined by the Diagnostic and Statistical Manual for
Mental Disorders Fourth Edition Text Revision (DSM-IV-TR). Patients may have comorbid
Anxiety Disorders, except for Obsessive Compulsive Disorder

- Tests negative for pregnancy at the time of enrollment based on a serum pregnancy test
and agrees to use a reliable method of birth control (for example, use of oral
contraceptives or Norplant a reliable barrier method of birth control diaphragms with
contraceptive jelly; cervical caps with contraceptive jelly; condoms with
contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence)
during the study and for 1 month following the last dose of study drug.

- Hamilton Depression Rating 17 Item Scale (HAMD-17) greater than 15 at Visits 1 and 2.

Exclusion Criteria:

- Have any current Axis I disorder other than major depressive disorder (MDD),
dysthymia, or any anxiety disorder; however, obsessive-compulsive disorder is
excluded.

- Have any previous or current diagnosis of bipolar disorder, obsessive-compulsive
disorder, schizophrenia, or other psychotic disorders.

- Lack of response of the current episode of major depression to two or more adequate
courses of antidepressant therapy at clinically appropriate dose for a minimum of 4
weeks or, in the judgment of the investigator, the patient meets criteria for
treatment-resistant depression.

- DSM-IV-TR-defined history of substance abuse or dependence within the past 6 months,
excluding nicotine and caffeine.

- Patients judged to be at serious suicidal risk in the opinion of the investigator.